Products - Renal cancer | Topic | NICE

Showing 8 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Kidney Cancer
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
28 October 2025
Expected publication date:
19 March 2026
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
27 March 2026
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
8 December 2027
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Renal cell carcinoma Pathways Pilot [ID6186]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Kidney Cancer Quality Standard
Status:
In development | In consultation
Consultation end date:
28 October 2025
Expected publication date:
TBC
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC